Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
Luger SM, Wang VX, Rowe JM, Litzow MR, Paietta E, Ketterling RP, Lazarus H, Rybka WB, Craig MD, Karp J, Cooper BW, Makary AZ, Kaminer LS, Appelbaum FR, Larson RA, Tallman MS. Luger SM, et al. Among authors: craig md. Leuk Res. 2021 Dec;111:106736. doi: 10.1016/j.leukres.2021.106736. Epub 2021 Oct 28. Leuk Res. 2021. PMID: 34773794 Free PMC article. Clinical Trial.
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes.
Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J, Pigneux A, Schiller GJ, Jung J, Jane Leonard E, Fingert H, Westervelt P. Goldberg SL, et al. Among authors: craig md. Leuk Res Rep. 2014 Jul 5;3(2):58-61. doi: 10.1016/j.lrr.2014.06.003. eCollection 2014. Leuk Res Rep. 2014. PMID: 25068104 Free PMC article.
A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
Cooper BW, Kindwall-Keller TL, Craig MD, Creger RJ, Hamadani M, Tse WW, Lazarus HM. Cooper BW, et al. Among authors: craig md. Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):428-432.e2. doi: 10.1016/j.clml.2015.02.017. Epub 2015 Feb 16. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25776192 Free PMC article. Clinical Trial.
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Altman JK, Zuckerman T, Koprivnikar J, McCloskey J, Kota V, Keng M, Frankfurt O, Abaza Y, Bixby DL, Emadi A, Burch M, Bhatnagar B, Luger SM, Percival ME, Wolach O, Craig M, Ganzel C, Roboz G, Levi I, Gourevitch A, Flaishon L, Tessler S, Blumberg C, Gengrinovitch S, Ben Yakar R, Rowe JM. Altman JK, et al. Blood Adv. 2023 Dec 26;7(24):7494-7500. doi: 10.1182/bloodadvances.2023010943. Blood Adv. 2023. PMID: 37903324 Free PMC article. Clinical Trial.
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A Jr, Laadem A, Seiter K. Cortes J, et al. J Clin Oncol. 2010 Sep 20;28(27):4207-13. doi: 10.1200/JCO.2009.26.8896. Epub 2010 Aug 16. J Clin Oncol. 2010. PMID: 20713865 Free PMC article. Clinical Trial.
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Faderl S, et al. J Clin Oncol. 2012 Jul 10;30(20):2492-9. doi: 10.1200/JCO.2011.37.9743. Epub 2012 May 14. J Clin Oncol. 2012. PMID: 22585697 Free PMC article. Clinical Trial.
Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Craig M, Hanna WT, Cabanillas F, Chen CS, Esseltine DL, Neuwirth R, O'Connor OA. Craig M, et al. Br J Haematol. 2014 Sep;166(6):920-8. doi: 10.1111/bjh.12991. Epub 2014 Jul 9. Br J Haematol. 2014. PMID: 25039282 Free article. Clinical Trial.
80 results